By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quidel announced on Friday that the US Food and Drug Administration has cleared for marketing two of its molecular tests, one for human metapneumovirus and the other for influenza A and B, making them the San Diego company's first FDA-cleared MDx tests.

The Quidel Molecular hMPV Assay is the first molecular test from the company to receive FDA 510(k) clearance, it said, adding it was launched in Europe after getting CE marked in September 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.